While supply headwinds have hit life science performance in recent years, long-term fundamentals have been reinforced by the pandemic. We expect a recovery in the short term and strong performance further out, but the sector is likely to remain a relatively small component of real estate portfolios.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services